109 related articles for article (PubMed ID: 35809269)
21. Matrix stiffness-mediated effects on stemness characteristics occurring in HCC cells.
You Y; Zheng Q; Dong Y; Xie X; Wang Y; Wu S; Zhang L; Wang Y; Xue T; Wang Z; Chen R; Wang Y; Cui J; Ren Z
Oncotarget; 2016 May; 7(22):32221-31. PubMed ID: 27050147
[TBL] [Abstract][Full Text] [Related]
22. CD44, SHH and SOX2 as novel biomarkers in esophageal cancer patients treated with neoadjuvant chemoradiotherapy.
Honing J; Pavlov KV; Mul VE; Karrenbeld A; Meijer C; Faiz Z; Smit JK; Hospers GA; Burgerhof JG; Kruyt FA; Kleibeuker JH; Plukker JT
Radiother Oncol; 2015 Oct; 117(1):152-8. PubMed ID: 26364884
[TBL] [Abstract][Full Text] [Related]
23. SOX2 promotes the migration and invasion of laryngeal cancer cells by induction of MMP-2 via the PI3K/Akt/mTOR pathway.
Yang N; Hui L; Wang Y; Yang H; Jiang X
Oncol Rep; 2014 Jun; 31(6):2651-9. PubMed ID: 24700142
[TBL] [Abstract][Full Text] [Related]
24. Stemness state regulators SALL4 and SOX2 are involved in progression and invasiveness of esophageal squamous cell carcinoma.
Forghanifard MM; Ardalan Khales S; Javdani-Mallak A; Rad A; Farshchian M; Abbaszadegan MR
Med Oncol; 2014 Apr; 31(4):922. PubMed ID: 24659265
[TBL] [Abstract][Full Text] [Related]
25. Loss of CD44 and SOX2 expression is correlated with a poor prognosis in esophageal adenocarcinoma patients.
Honing J; Pavlov KV; Meijer C; Smit JK; Boersma-van Ek W; Karrenbeld A; Burgerhof JG; Kruyt FA; Plukker JT
Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S657-64. PubMed ID: 24833101
[TBL] [Abstract][Full Text] [Related]
26. Stem signatures associating SOX2 antibody helps to define diagnosis and prognosis prediction with esophageal cancer.
Peng ZY; Wang QS; Li K; Chen SS; Li X; Xiao GD; Tang SC; Ren H; Wang Z; Sun X
Ann Med; 2022 Dec; 54(1):921-932. PubMed ID: 35382656
[TBL] [Abstract][Full Text] [Related]
27. Phosphorylated mTOR expression correlates with podoplanin expression and high tumor grade in esophageal squamous cell carcinoma.
Chuang WY; Chang YS; Chao YK; Yeh CJ; Ueng SH; Chang CY; Liu YH; Tseng CK; Chang HK; Wan YL; Hsueh C
Int J Clin Exp Pathol; 2015; 8(10):12757-65. PubMed ID: 26722465
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathologic significance and function of mammalian target of rapamycin activation in esophageal squamous cell carcinoma.
Kim SH; Chau GC; Jang YH; Lee SI; Pyo S; Um SH
Hum Pathol; 2013 Feb; 44(2):226-36. PubMed ID: 22944293
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis.
Li S; Wang Z; Huang J; Cheng S; Du H; Che G; Peng Y
BMC Cancer; 2016 Nov; 16(1):877. PubMed ID: 27835987
[TBL] [Abstract][Full Text] [Related]
30. SOX2 as a novel marker to predict neoplastic progression in Barrett's esophagus.
van Olphen S; Biermann K; Spaander MC; Kastelein F; Steyerberg EW; Stoop HA; Bruno MJ; Looijenga LH
Am J Gastroenterol; 2015 Oct; 110(10):1420-8. PubMed ID: 26323187
[TBL] [Abstract][Full Text] [Related]
31. SOX2/SALL4 stemness axis modulates Notch signaling genes to maintain self-renewal capacity of esophageal squamous cell carcinoma.
Forghanifard MM; Kasebi P; Abbaszadegan MR
Mol Cell Biochem; 2021 Feb; 476(2):921-929. PubMed ID: 33098486
[TBL] [Abstract][Full Text] [Related]
32. OCT4 but not SOX2 expression correlates with worse prognosis in surgical patients with triple-negative breast cancer.
Zhang JM; Wei K; Jiang M
Breast Cancer; 2018 Jul; 25(4):447-455. PubMed ID: 29536377
[TBL] [Abstract][Full Text] [Related]
33. RCC2 Promotes Esophageal Cancer Growth by Regulating Activity and Expression of the Sox2 Transcription Factor.
Calderon-Aparicio A; Yamamoto H; De Vitto H; Zhang T; Wang Q; Bode AM; Dong Z
Mol Cancer Res; 2020 Nov; 18(11):1660-1674. PubMed ID: 32801160
[TBL] [Abstract][Full Text] [Related]
34. AKT drives SOX2 overexpression and cancer cell stemness in esophageal cancer by protecting SOX2 from UBR5-mediated degradation.
Wang Z; Kang L; Zhang H; Huang Y; Fang L; Li M; Brown PJ; Arrowsmith CH; Li J; Wong J
Oncogene; 2019 Jun; 38(26):5250-5264. PubMed ID: 30894683
[TBL] [Abstract][Full Text] [Related]
35. Loss of SOX2 expression induces cell motility via vimentin up-regulation and is an unfavorable risk factor for survival of head and neck squamous cell carcinoma.
Bayo P; Jou A; Stenzinger A; Shao C; Gross M; Jensen A; Grabe N; Mende CH; Rados PV; Debus J; Weichert W; Plinkert PK; Lichter P; Freier K; Hess J
Mol Oncol; 2015 Oct; 9(8):1704-19. PubMed ID: 26040981
[TBL] [Abstract][Full Text] [Related]
36. Correlation of Cancer Stem-Cell Markers OCT4, SOX2, and NANOG with Clinicopathological Features and Prognosis in Operative Patients with Rectal Cancer.
You L; Guo X; Huang Y
Yonsei Med J; 2018 Jan; 59(1):35-42. PubMed ID: 29214774
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic down-regulation of SOX2 is an independent poor prognostic factor for hypopharyngeal cancers.
Avincsal MO; Jimbo N; Fujikura K; Shinomiya H; Otsuki N; Morimoto K; Furukawa T; Morita N; Maehara R; Itoh T; Nibu KI; Zen Y
Histopathology; 2018 Apr; 72(5):826-837. PubMed ID: 29143365
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical molecular phenotypes of gastric cancer based on SOX2 and CDX2 predict patient outcome.
Camilo V; Barros R; Celestino R; Castro P; Vieira J; Teixeira MR; Carneiro F; Pinto-de-Sousa J; David L; Almeida R
BMC Cancer; 2014 Oct; 14():753. PubMed ID: 25300947
[TBL] [Abstract][Full Text] [Related]
39. The Clinical and Prognostic Implications of Pluripotent Stem Cell Markers Expression and Their Correlation with the WNT signal pathway in Hepatocellular Carcinoma.
Osman NAA; Khalil AI; Yousef RK
Asian Pac J Cancer Prev; 2020 Oct; 21(10):2961-2970. PubMed ID: 33112555
[TBL] [Abstract][Full Text] [Related]
40. mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.
Garros-Regulez L; Aldaz P; Arrizabalaga O; Moncho-Amor V; Carrasco-Garcia E; Manterola L; Moreno-Cugnon L; Barrena C; Villanua J; Ruiz I; Pollard S; Lovell-Badge R; Sampron N; Garcia I; Matheu A
Expert Opin Ther Targets; 2016; 20(4):393-405. PubMed ID: 26878385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
